Contraindications and Precautions for Ketoconazole Use

Hepatotoxicity and Contraindications

Hepatotoxicity occurs in 10-20% of patients, typically within the first 6 months of treatment, though serious injury can occur at any time during therapy, as reported by The Lancet Diabetes and Endocrinology 1, 2
Protease inhibitors and certain antifungals are contraindicated when using oral ketoconazole due to strong CYP3A4 inhibition, as stated by Liver International 3
Concomitant use with ciclosporin, itraconazole, and tacrolimus is contraindicated, according to the Journal of Thrombosis and Haemostasis 4

Ketoconazole is listed as a strong P-glycoprotein inhibitor that can significantly alter dabigatran bioavailability, and acts as both CYP3A4 and P-gp inhibitor, causing important reduction in rivaroxaban clearance, as reported by the Journal of Thrombosis and Haemostasis 4
The American College of Clinical Pharmacology recommends careful consideration in patients with severe renal insufficiency (CrCl 15-29 mL/min) as these patients were excluded from major clinical trials, with guidance from the Journal of Thrombosis and Haemostasis 4

Men may experience hypogonadism and gynecomastia, which can limit prolonged treatment, as reported by The Lancet Diabetes and Endocrinology 1, 2
Menstrual irregularities can occur in women, according to MMWR Recommendations and Reports 5
Weekly serum ALT monitoring for the duration of treatment is required, with guidance from The Lancet Diabetes and Endocrinology 1